---
title: "Opdivo (nivolumab) in metastatic non-small cell lung cancer: Safety questions"
description: "Safety questions on Opdivo (nivolumab) in metastatic non-small cell lung cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects and Administration reactions. Questions: What are common side effects of Opdivo plus Yervoy in lung cancer? What serious side effects occurred with Opdivo plus Yervoy in Checkmate 227? What are common side effects of Opdivo, Yervoy, and chemo (Checkmate 9LA)? What serious side effects occurred with Opdivo, Yervoy, and chemotherapy (Checkmate 9LA)? 4 further questions follow. 8 questions quoted from 6 sources."
canonical: "https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/safety"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Opdivo (nivolumab) in metastatic non-small cell lung cancer: Safety questions

Manufacturer: Bristol-Myers Squibb Company  
Prescribing information: [Opdivo](https://packageinserts.bms.com/pi/pi_opdivo.pdf)

Safety questions that apply to every indication of Opdivo are on [Opdivo (nivolumab), all indications: Safety](https://www.evicenter.com/medical-information/opdivo/safety).

## Side effects

<a id="opdivo-side-effects-with-yervoy"></a>

### What are common side effects of Opdivo plus Yervoy in lung cancer?

Applies to: First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)

> “In Checkmate 227, the most common (≥20%) adverse reactions were fatigue (44%), rash (34%), decreased appetite (31%), musculoskeletal pain (27%), diarrhea/colitis (26%), dyspnea (26%), cough (23%), hepatitis (21%), nausea (21%), and pruritus (21%).”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/efficacy#:~:text=In%20Checkmate%20227%2C%20the%20most,nausea%20%2821%25%29%2C%20and%20pruritus%20%2821%25%29.)

> “Median number of doses was 9 OPDIVO IV and 3 YERVOY IV<sup>2</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Safety Profile for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/safety#:~:text=Median%20number%20of%20doses%20was%209%20OPDIVO%20IV%20and%203%20YERVOY)

> “With a minimum/median follow-up of 73.5/78.8 months, no new safety signals were identified with OPDIVO IV + YERVOY IV<sup>3,4</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Safety Profile for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/safety#:~:text=With%20a%20minimum%2Fmedian%20follow%2Dup%20of,with%20OPDIVO%20IV%20%2B%20YERVOY)

<a id="opdivo-serious-side-effects-with-yervoy"></a>

### What serious side effects occurred with Opdivo plus Yervoy in Checkmate 227?

Applies to: First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)

> “OPDIVO IV + YERVOY IV was discontinued in 24% of patients due to adverse reactions, and 53% had at least one dose withheld for an adverse reaction<sup>1</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Safety Profile for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/safety#:~:text=OPDIVO%20IV%20%2B%20YERVOY%20IV%20was,dose%20withheld%20for%20an%20adverse)

> “Serious adverse reactions occurred in 58% of patients receiving OPDIVO IV + YERVOY IV<sup>1</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Safety Profile for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/safety#:~:text=Serious%20adverse%20reactions%20occurred%20in,receiving%20OPDIVO%20IV%20%2B%20YERVOY)

> “The most frequent (≥2%) serious adverse reactions were pneumonia, diarrhea/colitis, pneumonitis, hepatitis, pulmonary embolism, adrenal insufficiency, and hypophysitis. Fatal adverse reactions occurred in 1.7% of patients; these included events of pneumonitis (4 patients), myocarditis, acute kidney injury, shock, hyperglycemia, multi-system organ failure, and renal failure<sup>1</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Safety Profile for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/safety#:~:text=The%20most%20frequent%20%28%E2%89%A52%25%29%20serious,multi%2Dsystem%20organ%20failure%2C%20and%20renal)

<a id="opdivo-side-effects-with-yervoy-and-chemo"></a>

### What are common side effects of Opdivo, Yervoy, and chemo (Checkmate 9LA)?

Applies to: First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)

> “In Checkmate 9LA, the most common (>20%) adverse reactions were fatigue (49%), musculoskeletal pain (39%), nausea (32%), diarrhea (31%), rash (30%), decreased appetite (28%), constipation (21%), and pruritus (21%).”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) + Chemo Efficacy Data for NSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-nsclc/efficacy#:~:text=In%20Checkmate%209LA%2C%20the%20most,constipation%20%2821%25%29%2C%20and%20pruritus%20%2821%25%29.)

> “Median number of doses was 9 for OPDIVO IV, 4 for YERVOY IV, and 2 cycles of chemo<sup>3</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) + Chemo Safety Profile for NSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-nsclc/safety#:~:text=Median%20number%20of%20doses%20was,IV%2C%20and%202%20cycles%20of)

<a id="opdivo-serious-side-effects-with-yervoy-and-chemo"></a>

### What serious side effects occurred with Opdivo, Yervoy, and chemotherapy (Checkmate 9LA)?

Applies to: First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)

> “OPDIVO IV + YERVOY IV with chemo was discontinued in 24% of patients due to adverse reactions and 56% had at least one dose withheld for an adverse reaction<sup>1</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) + Chemo Safety Profile for NSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-nsclc/safety#:~:text=OPDIVO%20IV%20%2B%20YERVOY%20IV%20with,dose%20withheld%20for%20an%20adverse)

> “Serious adverse reactions occurred in 57% of patients receiving OPDIVO IV + YERVOY IV with chemo<sup>1</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) + Chemo Safety Profile for NSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-nsclc/safety#:~:text=Serious%20adverse%20reactions%20occurred%20in,IV%20%2B%20YERVOY%20IV%20with)

> “The most frequent (>2%) serious adverse reactions were pneumonia, diarrhea, febrile neutropenia, anemia, acute kidney injury, musculoskeletal pain, dyspnea, pneumonitis, and respiratory failure. Fatal adverse reactions occurred in 7 (2%) patients, and included hepatic toxicity, acute renal failure, sepsis, pneumonitis, diarrhea with hypokalemia, and massive hemoptysis in the setting of thrombocytopenia<sup>1</sup>”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) + Chemo Safety Profile for NSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-nsclc/safety#:~:text=The%20most%20frequent%20%28%3E2%25%29%20serious,hemoptysis%20in%20the%20setting%20of)

<a id="opdivo-side-effects-second-line"></a>

### What are the side effects of Opdivo in previously treated NSCLC?

Applies to: Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO IV monotherapy (Checkmate 057 and 017)

> “The most common adverse reactions (reported in ≥20% of patients) were fatigue, musculoskeletal pain, cough, dyspnea, and decreased appetite
> Serious adverse reactions occurred in 46% of patients receiving OPDIVO IV
> The most frequent serious adverse reactions reported in at least 2% of patients receiving OPDIVO IV were pneumonia, pulmonary embolism, dyspnea, pyrexia, pleural effusion, pneumonitis, and respiratory failure
> OPDIVO IV was discontinued due to adverse reactions in 11% of patients
> 28% of patients receiving OPDIVO IV had a drug delay for an adverse reaction
> With 5 years minimum follow-up, no new safety signals were identified for OPDIVO IV<sup>2</sup>”

Source: [OPDIVO: OPDIVO Qvantig® Safety Profile for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/safety?tabKey=oivcheckmate057and017#:~:text=The%20most%20common%20adverse%20reactions,signals%20were%20identified%20for%20OPDIVO)

On the page, select: OPDIVO IV: Checkmate 057 and 017

<a id="opdivo-qvantig-side-effects"></a>

### What side effects did Opdivo Qvantig cause in Checkmate 67T (kidney cancer)?

Applies to: Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO QVANTIG monotherapy

> “The most common adverse reactions (≥10%) in patients treated with OPDIVO Qvantig (n=247) were musculoskeletal pain (31%), fatigue (20%), pruritus (16%), rash (15%), hypothyroidism (12%), diarrhea (11%), cough (11%), and abdominal pain (10%)<sup>1</sup>
> Serious adverse reactions occurred in 28% of patients who received OPDIVO Qvantig (n=247)<sup>1</sup>
> Serious adverse reactions in >1% of patients included pleural effusion (1.6%), pneumonitis (1.6%), hyperglycemia (1.2%), hyperkalemia (1.2%), hemorrhage (1.2%) and diarrhea (1.2%)<sup>1</sup>
> Fatal adverse reactions occurred in 3 patients (1.2%) who received OPDIVO Qvantig and included myocarditis, myositis, and colitis complications<sup>1</sup>
> Permanent discontinuation of OPDIVO Qvantig due to an adverse reaction occurred in 10% of patients<sup>1</sup>
> The most common adverse reaction which resulted in permanent discontinuation was pneumonitis (2%)<sup>1</sup>”

Source: [OPDIVO: OPDIVO Qvantig® Safety Profile for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/safety#:~:text=The%20most%20common%20adverse%20reactions,in%20permanent%20discontinuation%20was%20pneumonitis)

Note: Checkmate 67T enrolled adults with advanced or metastatic clear cell renal cell carcinoma; the safety page for previously treated metastatic NSCLC presents these data.

<a id="opdivo-pneumonitis"></a>

### How common is pneumonitis with Opdivo plus Yervoy in NSCLC?

Applies to: First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)

> “In NSCLC patients receiving OPDIVO 3 mg/kg every 2 weeks with YERVOY 1 mg/kg every 6 weeks, immune-mediated pneumonitis occurred in 9% (50/576) of patients, including Grade 4 (0.5%), Grade 3 (3.5%), and Grade 2 (4.0%). Four patients (0.7%) died due to pneumonitis.”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/efficacy#:~:text=In%20NSCLC%20patients%20receiving%20OPDIVO,%280.7%25%29%20died%20due%20to%20pneumonitis.)

> “The incidence of pneumonitis is higher in patients who have received prior thoracic radiation.”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/efficacy#:~:text=The%20incidence%20of%20pneumonitis%20is,have%20received%20prior%20thoracic%20radiation.)

## Administration reactions

<a id="opdivo-infusion-reactions"></a>

### Can Opdivo cause infusion reactions?

> “OPDIVO and YERVOY can cause severe infusion-related reactions. Discontinue OPDIVO and YERVOY in patients with severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions. Interrupt or slow the rate of infusion in patients with mild (Grade 1) or moderate (Grade 2) infusion-related reactions. In patients receiving OPDIVO monotherapy as a 60-minute infusion, infusion-related reactions occurred in 6.4% (127/1994) of patients. In a separate trial in which patients received OPDIVO monotherapy as a 60-minute infusion or a 30-minute infusion, infusion-related reactions occurred in 2.2% (8/368) and 2.7% (10/369) of patients, respectively.”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/efficacy#:~:text=OPDIVO%20and%20YERVOY%20can%20cause%20severe,2.7%25%20%2810%2F369%29%20of%20patients%2C%20respectively.)

## Related pages
- [Medical information: Opdivo (nivolumab): Metastatic non-small cell lung cancer](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer)
- [Indication](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/guidelines)
